Xencor, Inc Equity Securities, FV-NI, Unrealized Gain
Xencor, Inc (XNCR) reported Equity Securities, FV-NI, Unrealized Gain of $20.99 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-24.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGain · last filed 2022-02-24
- Xencor, Inc equity securities, fv-ni, unrealized gain for fiscal 2021 was $20.99M, a 19888.57% increase from fiscal 2020.
- Xencor, Inc equity securities, fv-ni, unrealized gain for fiscal 2020 was $105.00K.
| Period end | Equity Securities, FV-NI, Unrealized Gain 12 month |
|---|---|
| 2021-12-31 | $20.99M 10-K · filed 2022-02-24 |
| 2020-12-31 | $105.00K 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |